Prof. Yao Yu, MD, PhD
Deputy Head of Glioma Surgery · Director of Neuro-Oncology Immunology Lab, Huashan Hospital · Recipient of Wang Zhongcheng Award
Prof. Yao Yu, MD, PhD
Director, Neuro-Oncology Immunology Lab, Fudan Univ.
-
Hospital AffiliationHuashan Hospital, Fudan Univ.
-
Campus LocationMain Campus (VIP) & Hongqiao
-
Clinical LanguagesEnglish · Mandarin
-
Clinical Practice28+ Years Active Practice
-
Consultation Turnaround24–48 Hours Priority Review
Pioneering Microneurosurgical Resection & Advanced Immunotherapy for Glioma
Prof. Yao Yu, MD, PhD, is one of China's most celebrated neurosurgical oncologists, directing the Laboratory of Neuro-Oncology Immunology at Fudan University Neurosurgical Institute and serving as Deputy Head of the Glioma Subspecialty at Huashan Hospital. Mentored by Academician Zhou Liangfu, he specializes in high-precision surgical resection of malignant and recurrent gliomas, coupled with cutting-edge immunotherapy and alternating electric field therapies.
He underwent extensive clinical and laboratory fellowships at Mayo Clinic, Harvard Medical School's Dana-Farber Cancer Institute, and MD Anderson Cancer Center. Prof. Yao leads the national expert consensus panel for immune and targeted therapies in central nervous system tumors. He is widely recognized for his integrative multimodal approach, bridging radical supramarginal resection with personalized dendritic cell (DC) vaccines and Optune Tumor Treating Fields (TTFields).
Integrative Surgical Precision & Translational Immunotherapy
Supramarginal Glioma Resection
Utilizes 3.0T intraoperative MRI and high-definition exoscopic visualization to push beyond conventional anatomical margins while rigorously sparing motor and language function.
Dendritic Cell (DC) Vaccination
China's leading clinical researcher in patient-specific autologous dendritic cell vaccines, activating cytotoxic T-cell immunity against recurrent glioblastoma micro-clones.
Tumor Treating Fields (TTFields)
Expert in Optune treatment planning and compliance protocols, synergizing alternating electrical fields with maintenance temozolomide and anti-angiogenic therapies.
Complex Recurrent Case Strategy
Provides customized salvage pathways for post-chemoradiation progression, secondary glioblastoma, and pediatric brain tumors through molecular-guided clinical trials.
Distinguished National Recognition & Translational Research
GLIOMA IMMUNOTHERAPY & TTFIELDS EVALUATION
Request a Clinical Consultation with Prof. Yao Yu, MD, PhD
Submit your brain tumor histopathology, molecular NGS panels, and MRI/CT DICOM scans for personalized immunotherapy, Optune TTFields, and surgical triage review by Prof. Yao Yu. Our medical coordination team reviews all inquiries within 24–48 hours.